Benzinga | Sep 9, 2020 04:12PM EDT

Sonoma Pharmaceuticals And Te Arai BioFarma Announce Launch Of Nasocyn Nasal Care And Oracyn Oral Care Products In Australia

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, oral, nasal, and eye care and dermatological conditions, and its New Zealand and Australian partner, Te Arai BioFarma Ltd., today announced the launch of two new products available in Australia. Both of these new products are based on Sonoma's patented Microcyn(r) and Microdacyn(r) technology and are available without prescription through pharmacies.

Nasocyn(r) Nasal Care clears and cleans blocked nasal passages and sinus cavities and helps stop runny nose while reducing inflammation. Nasocyn Nasal Care is non-irritating and used for preventative and symptomatic care against cold and flu.

Oracyn(r) Oral Care spray helps treat infections in the throat and mouth. It is effective against bleeding, irritated and sensitive gums as well as mouth ulcers and sore throats. Oracyn is used as a mouth wash, gargle or rinse and relieves present symptoms while protecting from future infections.

For more information, visit https://www.microheal.co.nz/.

"These two new products complement our existing Microcyn product line-up perfectly," said Scott Lissington, Chief Operating Officer of Te Arai BioFarma. "We are pleased to bring these two new products to the Australian market and increase our presence in the Australasian human patient care and wound healing market."

Amy Trombly, Chief Executive Officer of Sonoma Pharmaceuticals added, "We are excited to partner with Te Arai BioFarma to develop and launch these promising products in their home market. Nasal and oral care are just two of the many effective treatments available based on our powerful Microcyn(r) technology. We will continue to work with Te Arai BioFarma and our other worldwide partners to expand the reach of Microcyn(r) technology around the world."